Certis Oncology Announces CLIA Certification for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
60
Certis Oncology Announces CLIA Certification for High-Complexity Testing

SAN DIEGO, July 16, 2018 (GLOBE NEWSWIRE) -- Certis Oncology Solutions , Inc., a new precision medicine company focused on individualized patient care, today announced that it has received its CLIA Certificate of Registration for High-Complexity Testing. Certis will utilize the certificate to implement Laboratory Developed Tests for its Patient-Derived Orthotopic Xenograft (PDOX) mouse models.

CLIA (Clinical Laboratory Improvement Amendments) refers to regulations enacted in 1988 to ensure quality standards for clinical laboratory testing. Zero deficiencies were cited in Certis’ application.

“Fewer than 10 percent of independent CLIA laboratories are certified to perform high-complexity tests, so this gives us a distinct competitive advantage in promoting our services,” said Peter Ellman, Certis CEO.  “We are now ramping up our operations, including expansion of our vivarium and tumor bank, which enables us to provide research services to pharmaceuticals and biotech companies that foster the development of new cancer drugs.”

Pre-Clinical and Oncology/Patient Services Certis’ innovative science fills the need for certainty. The Certis PDOX precision mouse modeling techniques provide oncologists with more timely and accurate selection of treatment therapies. The science has been proven with publication of more than 40 peer-reviewed studies that validate the effectiveness of the techniques.

Certis implements the same techniques in pre-clinical services provided to pharmaceutical and biotech companies. Certis is operational and currently provides services including identifying patient-specific therapy, cryopreservation of tumors and Contract Research Organization (CRO) services.

“Certis makes a positive impact on people living with cancer,” said James Berglund, Chairman of Certis’ Board of Directors. “Concurrent testing of multiple drugs enabled by PDOX models present oncologists with more treatment options – while reducing the time required to select each patient’s optimal treatment.”

“Certis Oncology is about the patients,” agreed Fritz C. Eilber, MD, UCLA Division of Surgical Oncology, and a member of Certis’ Board of Directors.  “The goal is to improve and significantly impact patient’s lives. The ultimate individualized medicine is to have your tumor modeled.”

Certis derives revenue from three services:

  1. Developing immortalized mouse models and cryopreserving individual patient tumors.
  2. Testing potential drug therapies in these models by collaborating with oncologists to identify drug therapies that are effective and ineffective for individual patients.
  3. Contract work for leading pharmaceutical and biotech companies.

About the Certis PDOX Technique Certis services are based on a technique known as PDOX: Patient-Derived Orthotopic Xenografts. (Orthotopic means “the correct place.”) We take a very small specimen of the human patient’s tumor and surgically implant it into the corresponding anatomic location (pancreas, liver, lung, etc.) in immunodeficient mice.

Using our techniques, we have demonstrated the ability to rapidly grow individual patient tumors in mice at a high rate.  The PDOX models more accurately replicate human tumor growth, metastasis and response to therapy, making it more immediately clinically relevant than other models. The data created by PDOX models has been used to obtain an experimental drug for a critically ill patient suffering from an aggressive cancer that was not in the standard treatment protocol. In this case, the data from the models resulted in FDA clearance of an off-market Investigational New Drug and the patient’s life was extended by more than two years with a high quality of life.

About Certis Oncology Solutions Certis Oncology Solutions was formed in 2016 with the mission to provide individualized precision patient care. Our patient-directed therapy enables oncologists to tailor and optimize therapies for patients suffering from aggressive cancers. We also provide pre-clinical services for pharmaceutical and biotech companies. The differentiators for all of our services are the Certis PDOX techniques. Certis is affiliated with leading cancer physicians at UCLA and Memorial Sloan Kettering.

Contact Evan Birkhead birkhead@certisoncology.com

Photos accompanying this announcement are available at http://www.globenewswire.com/NewsRoom/Attachm...06e4de8862

http://www.globenewswire.com/NewsRoom/Attachm...fb4e571d94

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 108

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 147

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
A Teen's Opera Encounter Inspires Decades of Passion

Updated Category News Views 58

Unraveling a Lifelong Opera Obsession Back in the dog-eared days of 1970, a teenager waltzed into the Metropolitan Opera and stumbled onto a passion that'd pulse alongside him for over half a century. Now, David E. Lapin rolls out his personal chronicle, 'A Sound Obsession: Fifty-Five Years of Opera at the Met.' Folks, we’re diving into a cultural tapestry that’s...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 57

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Medtronic's Bold Move to Own Carotid Market Full-Scale

Updated Category News Views 122

When a giant like Medtronic makes a move, you can bet investors take notice, and this latest acquisition is no exception. They’re reaching into their deep pockets to acquire Contego Medical, a company shaking up the world of carotid artery disease treatments. It’s a tactical strike to solidify their leadership in cardiovascular solutions. Medtronic's Bet on Innovation...

Continue Reading
Hermes AI: A New Era in Market Analysis?

Updated Category News Views 39

Revolution or Just Another App? In a world where stock market insights are as cryptic as hieroglyphs to the average Joe, here comes the Hermes AI Analyzer, breaking onto the scene and promising to translate Wall Street's complex lingo into plain, simple language. It's the brainchild of Turkish engineer Umut Tugrul, who has spent decades in the trenches of software...

Continue Reading
Rock & Roll Hall of Fame's 2026 Induction Triumph

Updated Category News Views 90

A Night of Unstoppable Talent The Rock & Roll Hall of Fame's 2026 Induction Ceremony and boy, what a spectacle it was. Held on a lively Saturday night, November 14, in Los Angeles, it wasn't just an event; it was an electrifying testament to music's profound impact. With the grand ceremony kicking off at the historic city of stars, this year's induction turned the dial to...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 17

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
Radiotherapy Suit Challenges New EviCore Guidelines

Updated Category News Views 94

Turning Up the Heat on EviCore Winter Park, Florida—home of sunshine, oranges, and now a heated legal standoff. On November 16, 2026, the Radiotherapy Access Alliance dropped a bombshell lawsuit against EviCore over its recent guideline flip-flop. EviCore reversed its stance on low-dose radiation therapy (LDRT) for arthritis and other pesky pain, leaving patients—and...

Continue Reading
NVIDIA Faces Turbulent Storm with CEO Resignation

Updated Category News Views 39

Huang's Unexpected Exit and NVIDIA's Rocky Road Well, talk about drama in Silicon Valley. When executives start stumbling, it's not just some PR nightmare—it's a full-on crisis. NVIDIA's co-founder and CEO Jensen Huang is calling it quits, and not on some smooth, idyllic note. No, this is the kind of exit that investors dread. You’ve got affairs, security concerns,...

Continue Reading

Top 5 Most Recently Viewed Articles

Warren Buffett's Wisdom: Rethinking Your Stock Strategy

Updated Category News Views 155

Billionaire investor Warren Buffett became a titan in finance through his distinctive approach to stock investing, one that flips conventional wisdom on its head. While most folks lose their heads when prices drop, Buffett sees opportunity. When stocks go down, he doesn’t cry; he gets excited. "I love it when the things we buy go down," he said in a reflective moment...

Continue Reading
Kenneth L Calloway's $452K Share Sale: What It Means for CENX

Updated Category News Views 220

Understanding the Recent Insider Trade in Century Aluminum In a notable move that has caught the attention of investors, Kenneth L Calloway, the Senior Vice President at Century Aluminum, recently sold a significant amount of stocks. The transaction, which took place recently and is detailed in an SEC filing, involved the sale of 16,450 shares valued at approximately...

Continue Reading
Jura Energy Corporation Releases Key Financial Information

Updated Category News Views 213

Jura Energy Corporation Financial Filings Overview Jura Energy Corporation has recently announced an important update regarding its financial performance. The company has filed its condensed consolidated interim financial statements for the periods ending June 30 for both 2025 and 2024 on SEDAR. Alongside these financial statements, Jura has also released its...

Continue Reading
Exploring the Surge in Edge Computing Growth and Its Impact

Updated Category News Views 207

Understanding Edge Computing Growth Dynamics The edge computing market is poised for significant growth, projected to increase by USD 19.6 billion during the period between 2024 and 2028. This advancement is primarily fueled by the rising demand for decentralized computing, aimed at minimizing latency in decision-making processes. Technological advancements heralding...

Continue Reading
Hiab's Q3 Report 2025: Navigating Challenges with Resilience

Updated Category News Views 239

Hiab's Financial Journey in Q3 2025: An Overview Hiab's latest quarterly report sheds light on the company's performance amidst swirling market uncertainties. The recent challenges stemmed primarily from lower sales figures in parts of their market, particularly in the United States, affecting profitability. Key Highlights of the Quarterly Performance The first major...

Continue Reading